Compared with monotherapy, kinase inhibitors targeting BRAF mutations (e.g., vemurafenib, dabrafenib) combined with MEK inhibitors (e.g., trametinib) have improved median overall survival (OS) and progression-free survival (PFS) rates in patients with unresectable advanced metastatic BRAF-V600-mutant melanoma (Robert et al., 2019; Dhillon, 2016). This evidence concerns the gene BRAF and melanoma.